Natural beta interferon as an initial treatment for the elderly with chronic hepatitis C

Komorizono, Yasuji; Sako, Katsumi

doi:10.1111/j.1572-0241.2003.07655.x

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sooner the treatment was started, the better the clinical results. 7 Short-term IFN-b therapy might be recommended as a first treatment for elderly patients with chronic hepatitis C. 8 Compared with IFN-a, IFN-b has less significant side effects. 9 Although side effects are a major concern in the elderly, no significant complications of IFN-b have been reported in this age group yet.…”

Section: Treatment Of Non-responders To Ifn-a Therapymentioning

confidence: 99%

“…29 Allograft rejection occurs in 15% to 100% of the kidney recipients treated with IFN-a. 8,30,31 Therefore, clinical trials with a plan to determine the efficacy of IFNs in allograft recipients face ethical difficulties. To our knowledge, there is no reliable evidence indicating the efficacy of the IFN-a therapy in achieving an SVR in transplant patients.…”

Section: Ifn-b Therapy In Renal Transplant and Dialysis Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Is β-interferon a promising therapeutic option for the management of hepatitis C?

Hosseini-Moghaddam

Mousavi

Alavian

2009

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Using interferon-alpha (IFN-alpha) as the conventional therapeutic antiviral drug, physicians generally achieve a treatment success of <50% in cases with chronic hepatitis C. Owing to the structural similarities between IFN-alpha and interferon-beta (IFN-beta), the latter is a candidate for obtaining sustained viral response. In this review, we have compiled the published information on the use of IFN-beta for the management of acute and chronic hepatitis C up to 2007. We have looked at the rates of success and side effects. IFN-beta might be helpful if IFN-alpha fails to achieve a favourable outcome. This antiviral drug may be helpful for the management of chronic hepatitis C in both age extremes, in case of a relapse after receiving IFN-alpha and for preventing the development of the carrier state after acute hepatitis C. Further studies are required on the efficacy of IFN-beta for the management of acute and chronic hepatitis C.

show abstract

Section: Treatment Of Non-responders To Ifn-a Therapymentioning

confidence: 99%

Section: Ifn-b Therapy In Renal Transplant and Dialysis Patientsmentioning

confidence: 99%